Candel Therapeutics (NASDAQ:CADL) Stock Price Target Lowered at Canaccord Genuity Group

Candel Therapeutics (NASDAQ:CADL – Free Report) had its price objective decreased by Canaccord Genuity Group from $25.00 to $13.00 in a research report sent to investors on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

CADL has been the subject of several other reports. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Jefferies Financial Group assumed coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Thursday, October 15th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Read Our Latest Research Report on CADL

Candel Therapeutics Trading Down 26.1%

Candel Therapeutics stock opened at $6.20 on Friday. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $14.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. The stock has a market capitalization of $474.42 million, a P/E ratio of -4.19 and a beta of -0.27. The stock has a 50-day simple moving average of $9.75 and a 200 day simple moving average of $8.39.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. Analysts expect that Candel Therapeutics will post -1.29 earnings per share for the current year.

Insider Buying and Selling

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Candel Therapeutics in the second quarter valued at approximately $51,181,000. Bank of America Corp DE acquired a new stake in Candel Therapeutics during the 2nd quarter worth approximately $2,873,000. Wellington Management Group LLP acquired a new stake in Candel Therapeutics during the 2nd quarter worth approximately $2,119,000. Bank of New York Mellon Corp bought a new stake in Candel Therapeutics in the 2nd quarter valued at $1,975,000. Finally, Janus Henderson Group PLC bought a new stake in Candel Therapeutics in the 1st quarter valued at $845,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics News Roundup

These are some of the CADL news items that stood out recently:

  • Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ expected loss of $0.34. Third-quarter results and corporate update
  • Negative Sentiment: The company now expects to submit its biologics license application for aglatimagene in mid-2027. The delay followed FDA discussions and pushed back a key potential catalyst, prompting sharp selling. Mid-2027 BLA plan
  • Negative Sentiment: Reports also cited a wider operating loss, adding to concerns as investors reassess the company’s timeline and financial outlook. Operating loss and FDA discussion

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Further Reading

Analyst Recommendations for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.